From: Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review
 | Direct evidence | Linked evidence | ||
---|---|---|---|---|
intervention studies | diagnostic accuracy study | intervention studies | ||
Population | • RhD-negative pregnant women without sensitization | • RhD-negative pregnant women without sensitization | • RhD-negative pregnant women without sensitization | |
Study intervention | • non-invasive prenatal RhD-testing of the fetus and omission of antenatal anti-D prophylaxis in the case of an RhD- negative fetus | • non-invasive prenatal RhD-testing of the fetus | • administration of anti-D prophylaxis | |
Control intervention | • anti-D prophylaxis for all RhD-negative pregnant women | • postnatal RhD-testing of the newborn | • no antenatal administration of anti-D prophylaxis | |
 |  |  | Benefits | Harms |
Patient-relevant outcomes/diagnostic accuracy measures | • mortality | • test accuracy (sensitivity, specificity, false-negative rate, false-positive rate) | • mortality | • mortality |
• HDFN (surrogate outcome: sensitization) | • HDFN (surrogate outcome: sensitization) | • adverse events | ||
• adverse events | • health-related quality of life | |||
• health-related quality of life | • health-related quality of life | |||
Study type | • RCTs | • prospective cohort studies | • RCTs | • RCTs |
• prospective, non-randomized controlled intervention studies | • prospective, non-randomized controlled intervention studies | • prospective, non-randomized controlled intervention studies | ||
• cohort studies (also retrospective or with historical controls) |